Phaseline

Companies › Jiangsu Jingze Biopharmaceutical

Jiangsu Jingze Biopharmaceutical: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Ophthalmology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Recombinant Human Truncated Plasmin Injection (JZB32)
Serine protease (truncated plasmin) that cleaves fibrin and other extracellular matrix pro
PLGPhase 2Vitreomacular Traction (VMT)Dec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07910630Recombinant Human Truncated Plasmin Injection (JZB32)Phase 2Vitreomacular Traction (VMT)OphthalmologyDec 2027

Targets

PLG (1)

Companies with the same targets

Ascension Health Supergene Youssef Yammine

Companies built like this

Qlaris Bio Aperta Biosciences ONL Therapeutics BioTheraVision Ascension Health

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.